Summit Therapeutics Closes Fully-Subscribed $500 Million Rights Offering
Summit Therapeutics has announced the successful closing of a $500 million rights offering, resulting in the sale of approximately 476.2 million shares at $1.05 per share. This offering generated net proceeds of about $499.5 million after expenses. With these funds, the company aims to support its operations, particularly focusing on ivonescimab (SMT112), into the second half of 2024. The company will host a Q4 earnings call on March 9, 2023, at 9:00 am ET.
- Successfully raised $500 million through rights offering.
- Net proceeds of roughly $499.5 million enhance cash runway.
- Focused funding aligns with the development of SMT112.
- None.
Successful capital raise provides a present-time cash runway into the second half of 2024
Company to host Q4 Earnings Call on
The rights offering resulted in the sale of approximately 476.2 million shares of the Company’s common stock, par value
With the successful completion of the rights offering, we believe that we have sufficient funds to carry out our planned operations into the second half of 2024. Our planned operations at this time are substantially focused on ivonescimab, known as SMT112 in our license territories, which include
“As an organization, we are enthusiastic about the opportunity we have moving forward with SMT112,” stated
A prospectus relating to the offering was filed with the
Summit today announced that it will host an earnings call to announce its fourth quarter 2022 financial results and provide an operational update for the Company on
Summit Therapeutics’ Mission Statement
To build a viable, long-lasting health care organization that assumes full responsibility for designing, developing, trial execution and enrollment, regulatory submission and approval, as well as successful commercialization of patient, physician, caregiver, and societal-friendly medicinal therapy intended to: improve quality of life, increase potential duration of life, and resolve serious medical healthcare needs. To identify and control promising product candidates based on exceptional scientific development and administrational expertise, develop our products in a rapid, cost-efficient manner, and to engage commercialization and/or development partners when appropriate.
We accomplish this by building a team of world class professional scientists and business administrators that apply their experience and knowledge to this mission. Team Summit exists to pose, strategize, and execute a path forward in medicinal therapeutic health care that places Summit in a well-deserved, top market share, leadership position. Team Summit assumes full responsibility for stimulating continuous expansion of knowledge, ability, capability, and well-being for all involved stakeholders and highly-valued shareholders.
About
Summit was founded in 2003 and our shares are listed on the Nasdaq Global Market (symbol ‘SMMT’). We are headquartered in
Summit Forward-looking Statements
Any statements in this press release about the Company’s future expectations, plans and prospects, including but not limited to, statements about the clinical and preclinical development of the Company’s product candidates, entry into and actions related to the Company’s partnership with Akeso Inc., the therapeutic potential of the Company’s product candidates, the potential commercialization of the Company’s product candidates, the timing of initiation, completion and availability of data from clinical trials, the potential submission of applications for marketing approvals, the impact of the COVID-19 pandemic on the Company’s operations and clinical trials, potential acquisitions and other statements containing the words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "would," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the results of our evaluation of the underlying data in connection with the development and commercialization activities for SMT112, the outcome of discussions with regulatory authorities, including the
View source version on businesswire.com: https://www.businesswire.com/news/home/20230303005082/en/
Contact Summit Investor Relations:
SVP, Corporate Strategy & Stakeholder Relations
investors@smmttx.com
Source:
FAQ
What was the amount raised in Summit Therapeutics' recent rights offering?
When will Summit Therapeutics host its Q4 earnings call?
What are the intended uses of the funds raised by Summit Therapeutics?
At what price per share was the rights offering conducted?